Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42165279 in Autism Spectrum Disorder
NCT03664232Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JNJ-42165279 in Autism Spectrum Disorder (ASD), sponsored by Janssen Pharmaceutical. Started Nov 2018; status: completed.
02
Drugs
JNJ-42165279
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03664232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664232.